ClinicalTrials.Veeva

Menu

Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial

McMaster University logo

McMaster University

Status

Unknown

Conditions

Feeding Intolerance in Premature Infants

Treatments

Drug: Glycerin Suppository
Other: Sham Suppository

Study type

Interventional

Funder types

Other

Identifiers

NCT02153606
Walton-MSA14-GlycerinSupp

Details and patient eligibility

About

All premature babies have problems with feeding and nutrition. Some can develop a life-threatening bowel infection necrotizing enterocolitis. This can result in the need for emergency surgery, loss of bowel, lifelong feeding problems, and death. Giving premature babies glycerin suppositories may be one way to stimulate the digestive tract and help prevent these problems. To see if this treatment works, the investigators need to study hundreds of premature babies in a large trial involving multiple hospitals. The purpose of this project is to carry out a small study first and make sure that the larger trial is feasible. The investigators will invite approximately 30 premature babies from the Neonatal Intensive Care Unit at McMaster University Medical Centre to participate in this study over a 6-month period. The investigators will focus on feasibility issues, including cost, safety, and rate of participation. This will allow us to rigorously test our study protocol and lay the groundwork for the larger study involving multiple hospitals.

Enrollment

30 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Gestational age 24-32 weeks OR
  • Birth weight 500-1500 grams

Exclusion criteria

  • Congenital gastrointestinal anomalies
  • Surgery within 48 hours of birth
  • Culture-proven sepsis*
  • Vasopressors within 6 hours of first intervention
  • Nitric oxide
  • Duct-dependent congenital heart defect requiring prostaglandins
  • Suspected coagulopathy (mucosal bleeding from any orifice)
  • Confirmed coagulopathy (any one of the following):
  • International Normalized Ratio greater than 1.4
  • Partial Thromboplastin Time greater than 39 seconds
  • Fibrinogen less than 1.00 grams/liter
  • Thrombocytopenia (platelet count less than 100 x 10^9/liter)**
  • Neutropenia (absolute neutrophil count less than 0.5 x 10^9/liter)
  • Complete meconium evacuation (2 normal bowel movements) within 48 hours of life
  • Parent or legal guardian unable to understand English

Note:

* C-reactive protein is not an exclusion criteria

** Indomethacin alone is not an exclusion criteria

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

30 participants in 2 patient groups

Glycerin Suppository
Active Comparator group
Treatment:
Drug: Glycerin Suppository
Sham Suppository
Sham Comparator group
Treatment:
Other: Sham Suppository

Trial contacts and locations

1

Loading...

Central trial contact

Henrietta Blinder, BSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems